NCT03373045

Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

Completed Last updated 24 September 2025

What this trial tests

trial in Asthma in 18 participants. Completed in 14 February 2025.

Timeline

27 February 2018

Primary endpoint
14 February 2025

14 February 2025

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	18
Start date	27 February 2018
Primary completion	14 February 2025
Estimated completion	14 February 2025
Sites	175 locations across Puerto Rico, United States

Conditions studied

• Asthma — all drugs for Asthma →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. Data will be collected from the healthcare provider in a uniform manner for every patient enrolled using an electronic case report form (eCRF). Data will be collected monthly from patients via web-based surveys. Patients will be followed until study discontinuation or the patient withdraws from the study or death, whichever occurs first. The expectation is that patients will be followed for a period of at least 3 years.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study.
   Menzies-Gow AN, McBrien C, Unni B, Porsbjerg CM, et al · · 2022 · cited 83× · PMID 35046670 · DOI 10.2147/jaa.s328653
2. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.
   Jackson DJ, Korn S, Mathur SK, Barker P, et al · · 2020 · cited 53× · PMID 32242310 · DOI 10.1007/s40264-020-00926-3
3. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments.
   Trevor J, Lugogo N, Carr W, Moore WC, et al · · 2021 · cited 32× · PMID 34273485 · DOI 10.1016/j.anai.2021.07.010
4. The CHRONICLE Study of US Adults with Subspecialist-Treated Severe Asthma: Objectives, Design, and Initial Results.
   Ambrose CS, Chipps BE, Moore WC, Soong W, et al · · 2020 · cited 31× · PMID 32765156 · DOI 10.2147/por.s251120
5. Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results.
   Ledford DK, Soong W, Carr W, Trevor J, et al · · 2023 · cited 19× · PMID 37506846 · DOI 10.1016/j.anai.2023.07.017
6. Biologic use and outcomes among adults with severe asthma treated by US subspecialists.
   Panettieri RA, Ledford DK, Chipps BE, Soong W, et al · · 2022 · cited 17× · PMID 35728746 · DOI 10.1016/j.anai.2022.06.012
7. Health-Related Quality of Life and Productivity Among US Patients with Severe Asthma.
   Soong W, Chipps BE, O'Quinn S, Trevor J, et al · · 2021 · cited 16× · PMID 34211280 · DOI 10.2147/jaa.s305513
8. Impact of the COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Subspecialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study.
   Moore WC, Ledford DK, Carstens DD, Ambrose CS. · · 2022 · cited 12× · PMID 36068863 · DOI 10.2147/jaa.s363217